EyePoint Pharmaceuticals (EYPT) Tops Q3 EPS by 17c

EyePoint Pharmaceuticals (NASDAQ: EYPT) reported Q3 EPS of ($0.33), $0.17 better than the analyst estimate of ($0.50). Revenue for the quarter came in at $15.2 million versus the consensus estimate of $7.86 million.

For earnings history and earnings-related data on EyePoint Pharmaceuticals (EYPT) click here.

You May Also Be Interested In

• Ennis (EBF) Reports In-Line Q1 EPS
• Syensqo SA (SYENS:BB) PT Raised to EUR74 at Deutsche Bank
• Tutor Perini launches $400M senior notes offering due 2033